Phase 2a Study of AR882 Plus Febuxostat or Allopurinol in Gout Patients

Condition:   Gout Interventions:   Drug: Group 1: AR882 + Febuxostat (FBX);   Drug: Group 2: AR882 + Allopurinol (ALLO) Sponsor:   Arthrosi Therapeutics Not yet recruiting

Source: ClinicalTrials.gov - November 7, 2019 Category: Research Source Type: clinical trials